Vivani Medical, Inc. (VANI) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal technology. The company operates two segments: the Biopharm Division (primary focus) and the Neurostimulation Division (Cortigent), which the company is attempting to spin off into a separate reporting entity by late 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6.78) million | $(6.30) million |
| Net Loss Per Share (Basic/Diluted) | $(0.08) | $(0.11) |
| Operating Expenses | $6.82 million | $6.56 million |
| Cash Used in Operating Activities | $(6.20) million | $(5.16) million |
| Cash Provided by Financing Activities | $9.71 million | $(0.17) million |
| Cash and Cash Equivalents (End of Period) | $19.75 million | $16.23 million |
| Total Assets | $42.35 million | $39.39 million |
| Total Liabilities | $23.27 million | $23.66 million |
| Stockholders' Equity | $19.09 million | $15.73 million |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $0.48 million (7.6%) compared to Q1 2025, driven primarily by a $0.2 million increase in Research and Development (R&D) expenses and a $0.1 million increase in General and Administrative (G&A) expenses.
- Financing Activity: Significant cash inflow from financing activities ($9.71 million) in Q1 2026 compared to a net outflow in Q1 2025. This was due to the issuance of common stock via the 2025 Private Sales Transactions ($5.65 million), a 2026 Registered Direct Offering ($2.17 million), and a 2026 Private Placement ($1.99 million).
- Other Income: Other income, net, decreased from $0.26 million in Q1 2025 to $0.04 million in Q1 2026, largely due to lower interest income and the write-off of accumulated other comprehensive income related to the Switzerland subsidiary.
- Share Count: Weighted average shares outstanding increased from 59.2 million in Q1 2025 to 81.3 million in Q1 2026 due to recent equity issuances.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates current cash resources will fund operations through the second quarter of 2027. This projection assumes the successful transition of the Cortigent subsidiary to a separate reporting company by Q2 or Q3 2026. If the spin-off fails and additional funding is not secured, the company may need to discontinue Cortigent's operations to preserve liquidity.
- Capital Requirements: The company expects to continue incurring operating losses and negative cash flows. It has entered into tranched financing agreements with expected remaining gross proceeds of approximately $7.0 million to be issued in 2026.
- Development Pipeline: The company plans to initiate Phase 1 clinical trials for lead candidates NPM-139 (semaglutide implant for weight management) and NPM-133 (semaglutide implant for type 2 diabetes) in mid-2026.
- Legal Contingencies:
- Pixium Vision SA: Pending appeal in the Paris Court of Appeal regarding a terminated MOU. A prior judgment ordered Vivani to pay approximately €1.55 million (net of prior payments). Vivani's appeal was struck out for failure to enforce the judgment; Vivani must request reinstatement within two years.
- Oppenheimer & Co. Inc.: Litigation seeking at least $1.625 million in damages. The court dismissed all claims except for breach of contract; discovery is ongoing.
- Risk Factors: Key risks include the inability to raise additional capital, failure to obtain regulatory approval for product candidates, reliance on third-party manufacturers, and the uncertainty surrounding the Cortigent spin-off.
Investor Verification Checklist
- Verify the status and timeline of the Cortigent spin-off, as liquidity projections beyond Q2 2027 are contingent on this transaction.
- Monitor the tranche closings of the 2025 Private Sales Transactions to ensure the expected $7.0 million in remaining proceeds is realized.
- Review the progress of the Paris Court of Appeal proceedings regarding Pixium Vision SA and the potential reinstatement of Vivani's appeal.
- Confirm the initiation of Phase 1 clinical trials for NPM-139 and NPM-133 in mid-2026 as planned.
- Assess the impact of the Oppenheimer litigation on future capital raising efforts and potential liability exposure.